Treatment patterns and outcomes according to age among older patients with early breast cancer: a retrospective study

Breast cancer is a disease that grows more common as people live longer, simply because the population itself is aging. In many parts of the world, including Japan, a significant portion of the population is now over sixty-five, and with that shift comes a rise in cancer diagnoses among older adults. For decades, doctors have relied on a standard set of treatments for early-stage breast cancer, including surgery to remove the tumor, radiation to kill remaining cells, and drugs like chemotherapy or hormone therapy to stop the cancer from returning. These treatments have saved countless lives, but they were largely designed and tested on younger, healthier people. When a patient is very old, the decision to use strong drugs becomes complicated. The body may not be able to handle the side effects, and other health issues might pose a greater threat to life than the cancer itself. This leaves doctors in a difficult position: they need to know if the standard treatments are still necessary for the oldest patients, or if a gentler approach is just as effective.

A team of researchers at Tokyo Women's Medical University Yachiyo Medical Center set out to look at how this plays out in real life. They examined the medical records of 171 women and men, all aged sixty-five or older, who had early-stage breast cancer and underwent surgery between 2007 and 2016. The researchers split these patients into two groups: those between sixty-five and seventy-four years old, and those who were seventy-five or older. They wanted to see if the older group received different care and, if so, whether that difference changed their chances of survival. The study focused on a specific group of patients who, based on the size of their tumors or the behavior of their cancer cells, would typically be considered candidates for chemotherapy. The goal was not to run a new experiment, but to observe what actually happened in a hospital setting over a ten-year period.

The results revealed a striking difference in how the two age groups were treated. While the tumors in both groups were similar in size and biological behavior, the patients aged seventy-five and older were far less likely to receive chemotherapy. In the younger group, more than half of the patients received these drugs, but in the oldest group, only three people out of seventy received chemotherapy. The older patients were also less likely to receive radiation therapy or targeted drugs that attack a specific protein called HER2, which can drive cancer growth. However, the use of hormone therapy, a gentler treatment that blocks the hormones fueling the cancer, remained about the same for both groups. The doctors appeared to be making these choices based on the patients' overall health and ability to tolerate treatment, rather than just the characteristics of the tumor itself.

Despite receiving much less aggressive treatment, the oldest patients did not fare worse in terms of their cancer coming back. The researchers tracked the patients for several years to see if the disease returned or if they passed away. They found that the rate of the cancer returning, known as disease-free survival, was statistically similar between the two age groups. Similarly, the rate of death specifically caused by breast cancer was also comparable. This suggests that for these older patients, the decision to skip chemotherapy did not lead to a higher rate of cancer recurrence. However, the overall survival rate, which counts deaths from any cause, was lower in the oldest group. This is not surprising, as people over seventy-five are more likely to die from other age-related conditions, such as heart disease, rather than from their cancer.

The study also looked at what factors actually predicted a patient's outcome. The researchers found that the age of the patient, the stage of the cancer, and how fast the tumor cells were dividing were the strongest indicators of whether a patient would survive. Interestingly, whether a patient received chemotherapy or not did not show up as a major factor in predicting survival for this specific group of older patients. This does not mean chemotherapy is useless; rather, it highlights that in the real world, doctors are already selecting patients carefully. The three oldest patients who did receive chemotherapy were likely those deemed strong enough to handle it, while the others were spared the harsh side effects because their doctors judged the risks to be too high.

The authors are careful to state that their findings should not be taken as proof that chemotherapy offers no benefit to people over seventy-five. Because so few patients in that age group received the treatment, the study cannot definitively prove that the drug works or fails in this population. Instead, the study serves as a snapshot of current medical practice. It shows that doctors are already moving away from a "one size fits all" approach and are instead tailoring treatment to the individual. They are weighing the biology of the tumor against the physical reality of the patient. The study supports the idea that for older adults with early breast cancer, a personalized plan that considers the patient's overall health and preferences is a valid and effective strategy, even if it means using fewer drugs than the standard protocol. As the global population continues to age, this kind of careful, individualized decision-making will become increasingly important for ensuring that older patients receive the right care without unnecessary harm.